PT99757B - Processo para a preparacao de um sal sulfato de 3-{2-(dimetilamino)-etil}-n-metil-1h-indole-5-metanossulfonamida e de composicoes farmaceuticas que o contem - Google Patents

Processo para a preparacao de um sal sulfato de 3-{2-(dimetilamino)-etil}-n-metil-1h-indole-5-metanossulfonamida e de composicoes farmaceuticas que o contem Download PDF

Info

Publication number
PT99757B
PT99757B PT99757A PT9975791A PT99757B PT 99757 B PT99757 B PT 99757B PT 99757 A PT99757 A PT 99757A PT 9975791 A PT9975791 A PT 9975791A PT 99757 B PT99757 B PT 99757B
Authority
PT
Portugal
Prior art keywords
solution
methyl
indole
dimethylamino
ethyl
Prior art date
Application number
PT99757A
Other languages
English (en)
Portuguese (pt)
Other versions
PT99757A (pt
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PT99757A publication Critical patent/PT99757A/pt
Publication of PT99757B publication Critical patent/PT99757B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
PT99757A 1990-12-12 1991-12-11 Processo para a preparacao de um sal sulfato de 3-{2-(dimetilamino)-etil}-n-metil-1h-indole-5-metanossulfonamida e de composicoes farmaceuticas que o contem PT99757B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (2)

Publication Number Publication Date
PT99757A PT99757A (pt) 1992-12-31
PT99757B true PT99757B (pt) 1999-05-31

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99757A PT99757B (pt) 1990-12-12 1991-12-11 Processo para a preparacao de um sal sulfato de 3-{2-(dimetilamino)-etil}-n-metil-1h-indole-5-metanossulfonamida e de composicoes farmaceuticas que o contem

Country Status (36)

Country Link
US (2) US5554639A (enExample)
EP (1) EP0490689B1 (enExample)
JP (1) JP2994037B2 (enExample)
KR (1) KR100211479B1 (enExample)
CN (2) CN1030890C (enExample)
AP (1) AP230A (enExample)
AT (1) ATE119881T1 (enExample)
AU (1) AU650706B2 (enExample)
BE (1) BE1005085A3 (enExample)
CA (1) CA2098302C (enExample)
CH (1) CH684192A5 (enExample)
CY (1) CY2005A (enExample)
CZ (1) CZ281931B6 (enExample)
DE (1) DE69108200T2 (enExample)
DK (1) DK0490689T3 (enExample)
EG (1) EG20219A (enExample)
ES (1) ES2069836T3 (enExample)
FR (1) FR2670487B1 (enExample)
GB (2) GB9026998D0 (enExample)
GR (1) GR3015430T3 (enExample)
HK (1) HK82697A (enExample)
HU (1) HU211937A9 (enExample)
IE (1) IE62894B1 (enExample)
IL (1) IL100330A (enExample)
IS (1) IS1706B (enExample)
IT (1) IT1252868B (enExample)
MX (1) MX9102501A (enExample)
MY (1) MY109265A (enExample)
NL (1) NL9102071A (enExample)
NZ (1) NZ240942A (enExample)
PT (1) PT99757B (enExample)
RU (1) RU2108328C1 (enExample)
TW (2) TW300886B (enExample)
WO (1) WO1992010477A1 (enExample)
YU (1) YU48926B (enExample)
ZA (1) ZA919750B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097208C (en) * 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2008049116A2 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CN102046621B (zh) 2008-05-27 2014-11-12 生物区科学管理控股有限公司 抗病毒盐
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
CA2729346A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP6897971B2 (ja) 2015-05-15 2021-07-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 関節炎を処置するための、方法および組成物
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
WO2019094469A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CA3172358A1 (en) * 2020-02-27 2021-09-02 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EP0490689B1 (en) 1995-03-15
EP0490689A1 (en) 1992-06-17
YU48926B (sh) 2002-12-10
GR3015430T3 (en) 1995-06-30
ITRM910922A0 (it) 1991-12-11
IS3790A7 (is) 1992-06-13
MY109265A (en) 1996-12-31
ES2069836T3 (es) 1995-05-16
CN1128259A (zh) 1996-08-07
NZ240942A (en) 1994-03-25
EG20219A (en) 1997-11-30
DE69108200T2 (de) 1995-07-20
ZA919750B (en) 1992-10-28
GB9026998D0 (en) 1991-01-30
HU211937A9 (en) 1996-01-29
IL100330A (en) 1996-06-18
HK82697A (en) 1997-06-27
US5705520A (en) 1998-01-06
DE69108200D1 (de) 1995-04-20
CN1030890C (zh) 1996-02-07
NL9102071A (nl) 1992-07-01
AP9100339A0 (en) 1992-01-31
GB9126297D0 (en) 1992-02-12
DK0490689T3 (da) 1995-05-22
US5554639A (en) 1996-09-10
MX9102501A (es) 1992-09-01
TW300886B (enExample) 1997-03-21
CH684192A5 (fr) 1994-07-29
ATE119881T1 (de) 1995-04-15
IE914317A1 (en) 1992-06-17
CA2098302C (en) 2001-10-16
FR2670487A1 (fr) 1992-06-19
IT1252868B (it) 1995-06-28
CZ281931B6 (cs) 1997-04-16
GB2251614A (en) 1992-07-15
CN1050831C (zh) 2000-03-29
GB2251614B (en) 1994-12-14
CN1063099A (zh) 1992-07-29
CZ114093A3 (en) 1994-02-16
CY2005A (en) 1997-12-05
IS1706B (is) 1998-12-10
FR2670487B1 (fr) 1993-08-20
JPH06503560A (ja) 1994-04-21
CA2098302A1 (en) 1992-06-13
IE62894B1 (en) 1995-03-08
YU191491A (sh) 1994-04-05
IL100330A0 (en) 1992-09-06
ITRM910922A1 (it) 1993-06-11
BE1005085A3 (fr) 1993-04-13
KR100211479B1 (ko) 1999-08-02
PT99757A (pt) 1992-12-31
AP230A (en) 1993-01-27
WO1992010477A1 (en) 1992-06-25
TW205035B (enExample) 1993-05-01
RU2108328C1 (ru) 1998-04-10
JP2994037B2 (ja) 1999-12-27
AU9072091A (en) 1992-07-08
AU650706B2 (en) 1994-06-30

Similar Documents

Publication Publication Date Title
US5705520A (en) Medicaments
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
JPH0639378B2 (ja) 医薬組成物
BRPI0406674B1 (pt) composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
PT92188B (pt) Processo para a preparacao de uma solucao aquosa contendo acido cromoglicico e salbutamol
JP2019019075A (ja) ペメトレキセド含有液状医薬組成物
US5834502A (en) Triazolylmethyl-indole ethylamine bisulfate salt
CN102204882A (zh) 布洛芬的药物组合物
EP0840733B1 (en) A triazolylmethyl-indole ethylamine bisulfate salt
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid
TW202428273A (zh) 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物
SI9400157A (en) Sulphate salt of a substituted triazole, its pharmaceutical compositions and their use as medicaments

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920907

FG3A Patent granted, date of granting

Effective date: 19990219

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20130819

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20140219